keyword
MENU ▼
Read by QxMD icon Read
search

Entinostat

keyword
https://www.readbyqxmd.com/read/27892955/erratum-the-histone-deacetylase-inhibiting-drug-entinostat-induces-lipid-accumulation-in-differentiated-heparg-cells
#1
Abigail D G Nunn, Tullio Scopigno, Natalia Pediconi, Massimo Levrero, Henning Hagman, Juris Kiskis, Annika Enejder
No abstract text is available yet for this article.
November 28, 2016: Scientific Reports
https://www.readbyqxmd.com/read/27797970/molecular-pathways-maintaining-mapk-inhibitor-sensitivity-by-targeting-nonmutational-tolerance
#2
Michael P Smith, Claudia Wellbrock
Targeting hyperactive MAPK signaling has proven to be an effective treatment for a variety of different cancers. Responses to the BRAF inhibitors vemurafenib and dabrafenib and the MEK inhibitors trametinib and cobimetinib are, however, transient, and complete remission is rarely observed; rather, outgrowth of resistant clones within progressed tumors appears inevitable. These resistant tumors display great heterogeneity, which poses a major challenge to any salvage therapy. Recent focus has, therefore, been on the early dynamics of inhibitor response during tumor regression...
October 19, 2016: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/27792246/inhibition-of-histone-deacetylases-in-melanoma-a-perspective-from-bench-to-bedside
#3
REVIEW
Eva Hornig, Markus V Heppt, Saskia A Graf, Thomas Ruzicka, Carola Berking
Histone deacetylases (HDACs) are critically involved in epigenetic gene regulation through alterations of the chromatin status of DNA. Aberrant expression, dysregulation of their enzymatic activity or imbalances between HDACs and histone acetyltransferases are likely involved in the development and progression of cancer. Pharmacologic inhibition of HDACs shows potent antitumor activity in a panel of malignancies such as colon or gastric cancer and multiple myeloma. In this review, we summarize the current knowledge of HDACs in melanoma and evaluate the application of HDAC inhibition from an experimental and clinical perspective...
November 2016: Experimental Dermatology
https://www.readbyqxmd.com/read/27765934/patient-derived-mouse-models-of-cancer-need-to-be-orthotopic-in-order-to-evaluate-targeted-anti-metastatic-therapy
#4
Yukihiko Hiroshima, Ali Maawy, Yong Zhang, Nan Zhang, Takashi Murakami, Takashi Chishima, Kuniya Tanaka, Yasushi Ichikawa, Michael Bouvet, Itaru Endo, Robert M Hoffman
Patient-derived xenograft (PDX) mouse models of cancer are emerging as an important component of personalized precision cancer therapy. However, most models currently offered to patients contain their tumors subcutaneously-transplanted in immunodeficient mice, which rarely metastasize. In contrast, orthotopic-transplant patient-derived models, termed patient-derived orthotopic xenografts (PDOX), usually metastasize as in the patient. We have demonstrated in the present report why orthotopic models are so important for the patient, since primary and metastatic tumors developed in an orthotopic model can have differential chemosensitivity, not detectable in standard subcutaneous tumor models...
September 28, 2016: Oncotarget
https://www.readbyqxmd.com/read/27761810/assessment-of-hdaci-induced-protein-cleavage-by-caspases
#5
Fabian Treude, Tobias Gladbach, Jacqueline Plaster, Jörg Hartkamp
Aberrant histone deacetylase (HDAC) activity often correlates with neoplastic transformation and inhibition of HDACs by small molecules has emerged as a promising strategy to treat hematological malignancies in particular. Treatment with HDAC inhibitors (HDACis) often prompts tumor cells to undergo apoptosis, thereby causing a caspase-dependent cleavage of target proteins. An unexpectedly large number of proteins are in vivo caspase substrates and defining caspase-mediated substrate specificity is a major challenge...
2017: Methods in Molecular Biology
https://www.readbyqxmd.com/read/27705911/targeting-sall4-by-entinostat-in-lung-cancer
#6
Kol Jia Yong, Ailing Li, Wen-Bin Ou, Clarice Kit Yee Hong, Wenxiu Zhao, Fei Wang, Hiro Tatetsu, Benedict Yan, Lihua Qi, Jonathan A Fletcher, Henry Yang, Ross Soo, Daniel G Tenen, Li Chai
The overall survival of lung cancer patients remains dismal despite the availability of targeted therapies. Oncofetal protein SALL4 is a novel cancer target. We herein report that SALL4 was aberrantly expressed in a subset of lung cancer patients with poor survival. SALL4 silencing by RNA interference or SALL4 peptide inhibitor treatment led to impaired lung cancer cell growth. Expression profiling of SALL4-knockdown cells demonstrated that both the EGFR and IGF1R signaling pathways were affected. Connectivity Map analysis revealed the HDAC inhibitor entinostat as a potential drug in treating SALL4-expressing cancers, and this was confirmed in 17 lung cancer cell lines...
September 26, 2016: Oncotarget
https://www.readbyqxmd.com/read/27633343/entinostat-up-regulates-the-camp-gene-encoding-ll-37-via-activation-of-stat3-and-hif-1%C3%AE-transcription-factors
#7
Erica Miraglia, Frank Nylén, Katarina Johansson, Elias Arnér, Marcus Cebula, Susan Farmand, Håkan Ottosson, Roger Strömberg, Gudmundur H Gudmundsson, Birgitta Agerberth, Peter Bergman
Bacterial resistance against classical antibiotics is a growing problem and the development of new antibiotics is limited. Thus, novel alternatives to antibiotics are warranted. Antimicrobial peptides (AMPs) are effector molecules of innate immunity that can be induced by several compounds, including vitamin D and phenyl-butyrate (PBA). Utilizing a luciferase based assay, we recently discovered that the histone deacetylase inhibitor Entinostat is a potent inducer of the CAMP gene encoding the human cathelicidin LL-37...
2016: Scientific Reports
https://www.readbyqxmd.com/read/27619199/differentiation-therapy-in-poor-risk-myeloid-malignancies-results-of-companion-phase-ii-studies
#8
Kelly J Norsworthy, Eunpi Cho, Jyoti Arora, Jeanne Kowalski, Hua-Ling Tsai, Erica Warlick, Margaret Showel, Keith W Pratz, Lesley A Sutherland, Steven D Gore, Anna Ferguson, Sarah Sakoian, Jackie Greer, Igor Espinoza-Delgado, Richard J Jones, William H Matsui, B Douglas Smith
Pre-clinical data in non-M3 AML supports the use of differentiation therapy, but clinical activity has been limited. Myeloid growth factors can enhance anti-leukemic activity of differentiating agents in vitro. We conducted companion phase II trials investigating sargramostim (GM-CSF) 125μg/m(2)/day plus 1) bexarotene (BEX) 300mg/m(2)/day or 2) entinostat (ENT) 4-8mg/m(2)/week in patients with MDS or relapsed/refractory AML. Primary endpoints were response after at least two treatment cycles and toxicity. 26 patients enrolled on the BEX trial had a median of 2 prior treatments and 24 enrolled on the ENT trial had a median of 1...
October 2016: Leukemia Research
https://www.readbyqxmd.com/read/27576506/histone-deacetylase-inhibitors-induce-proteolysis-of-activated-cdc42-associated-kinase-1-in-leukemic-cells
#9
Nisintha Mahendrarajah, Ramin Paulus, Oliver H Krämer
PURPOSE: Activated CDC42-associated kinase-1 (ACK1/TNK2) and epigenetic regulators of the histone deacetylase (HDAC) family regulate the proliferation and survival of leukemic cells. 18 HDACs fall into four classes (I-IV). We tested the impact of clinically relevant histone deacetylase inhibitors (HDACi) on ACK1 and if such drugs combine favorably with the therapeutically used ACK1 inhibitor Dasatinib. METHODS: We applied the broad-range HDACi Panobinostat/LBH589 and the class I HDAC-specific inhibitor Entinostat/MS-275 to various acute and chronic myeloid leukemia cells (AML/CML)...
November 2016: Journal of Cancer Research and Clinical Oncology
https://www.readbyqxmd.com/read/27551531/an-epithelial-marker-promoter-induction-screen-identifies-histone-deacetylase-inhibitors-to-restore-epithelial-differentiation-and-abolishes-anchorage-independence-growth-in-cancers
#10
H M Tang, K T Kuay, P F Koh, M Asad, T Z Tan, V Y Chung, S C Lee, J P Thiery, Ry-J Huang
Epithelial-mesenchymal transition (EMT), a crucial mechanism in development, mediates aggressiveness during carcinoma progression and therapeutic refractoriness. The reversibility of EMT makes it an attractive strategy in designing novel therapeutic approaches. Therefore, drug discovery pipelines for EMT reversal are in need to discover emerging classes of compounds. Here, we outline a pre-clinical drug screening platform for EMT reversal that consists of three phases of drug discovery and validation. From the Phase 1 epithelial marker promoter induction (EpI) screen on a library consisting of compounds being approved by Food and Drug Administration (FDA), Vorinostat (SAHA), a histone deacetylase inhibitor (HDACi), is identified to exert EMT reversal effects by restoring the expression of an epithelial marker, E-cadherin...
2016: Cell Death Discovery
https://www.readbyqxmd.com/read/27499916/hr23b-expression-is-a-potential-predictive-biomarker-for-hdac-inhibitor-treatment-in-mesenchymal-tumours-and-is-associated-with-response-to-vorinostat
#11
Michaela Angelika Ihle, Sabine Merkelbach-Bruse, Wolfgang Hartmann, Sebastian Bauer, Nancy Ratner, Hiroshi Sonobe, Jun Nishio, Olle Larsson, Pierre Åman, Florence Pedeutour, Takahiro Taguchi, Eva Wardelmann, Reinhard Buettner, Hans-Ulrich Schildhaus
Histone deacetylases (HDAC) are key players in epigenetic regulation of gene expression and HDAC inhibitor (HDACi) treatment seems to be a promising anticancer therapy in many human tumours, including soft tissue sarcomas. HR23b has been shown to be a potential biomarker for sensitivity to HDACi therapy in cutaneous T-cell lymphoma and hepatocellular carcinoma. We aimed to evaluate HR23b as a candidate biomarker for HDACi response in sarcomas and gastrointestinal stromal tumours (GIST). Therefore, HR23b expression was analysed comprehensively by western blot in sarcoma and GIST cell lines covering all major clinically relevant subtypes...
April 2016: Journal of Pathology. Clinical Research
https://www.readbyqxmd.com/read/27474150/flip-a-targetable-mediator-of-resistance-to-radiation-in-non-small-cell-lung-cancer
#12
Kylie A McLaughlin, Zsuzsanna Nemeth, Conor A Bradley, Luke Humphreys, Izabela Stasik, Catherine Fenning, Joanna Majkut, Catherine Higgins, Nyree Crawford, Caitriona Holohan, Patrick G Johnston, Timothy Harrison, Gerard G Hanna, Karl T Butterworth, Kevin M Prise, Daniel B Longley
Resistance to radiotherapy due to insufficient cancer cell death is a significant cause of treatment failure in non-small cell lung cancer (NSCLC). The endogenous caspase-8 inhibitor FLIP is a critical regulator of cell death that is frequently overexpressed in NSCLC and is an established inhibitor of apoptotic cell death induced via the extrinsic death receptor pathway. Apoptosis induced by ionizing radiation (IR) has been considered to be mediated predominantly via the intrinsic apoptotic pathway; however, we found that IR-induced apoptosis was significantly attenuated in NSCLC cells when caspase-8 was depleted using RNA interference (RNAi), suggesting involvement of the extrinsic apoptosis pathway...
October 2016: Molecular Cancer Therapeutics
https://www.readbyqxmd.com/read/27330528/hdac-inhibitors-ms-275-and-salermide-potentiates-the-anticancer-effect-of-ef24-in-human-pancreatic-cancer-cells
#13
Atiye Seda Yar Saglam, Akin Yilmaz, Hacer Ilke Onen, Ebru Alp, Handan Kayhan, Abdullah Ekmekci
Histone deacetylases (HDACs) play a major role in the regulation of chromatin structure and gene expression by changing acetylation status of histone and non-histone proteins. MS-275 (entinostat, MS) is a well-known benzamide-based HDACI and Salermide (SAL), a reverse amide compound HDACI, have antiproliferative effects on several human cancer cells. In this study, we aimed to investigate the effects of HDACIs (MS and SAL) alone and/or combined use with EF24 (EF), a novel synthetic curcumin analog, on human pancreatic cancer cell line (BxPC-3)...
2016: EXCLI journal
https://www.readbyqxmd.com/read/27320682/the-histone-deacetylase-inhibiting-drug-entinostat-induces-lipid-accumulation-in-differentiated-heparg-cells
#14
Abigail D G Nunn, Tullio Scopigno, Natalia Pediconi, Massimo Levrero, Henning Hagman, Juris Kiskis, Annika Enejder
Dietary overload of toxic, free metabolic intermediates leads to disrupted insulin signalling and fatty liver disease. However, it was recently reported that this pathway might not be universal: depletion of histone deacetylase (HDAC) enhances insulin sensitivity alongside hepatic lipid accumulation in mice, but the mechanistic role of microscopic lipid structure in this effect remains unclear. Here we study the effect of Entinostat, a synthetic HDAC inhibitor undergoing clinical trials, on hepatic lipid metabolism in the paradigmatic HepaRG liver cell line...
2016: Scientific Reports
https://www.readbyqxmd.com/read/27190263/promoter-methylation-status-of-tumor-suppressor-genes-and-inhibition-of-expression-of-dna-methyltransferase-1-in-non-small-cell-lung-cancer
#15
Bangqing Liu, Jianfei Song, Jiaqiang Luan, Xiaolin Sun, Jian Bai, Haiyong Wang, Angui Li, Lifei Zhang, Xiaoyan Feng, Zhenzong Du
DNA methylation is an epigenetic DNA modification catalyzed by DNA methyltransferase 1 (DNMT1). The purpose of this study was to investigate DNMT1 gene and protein expression and the effects of methylation status on tumor suppressor genes in human non-small cell lung cancer (NSCLC) cell lines grown in vitro and in vivo Human lung adenocarcinoma cell lines, A549 and H838, were grown in vitro and inoculated subcutaneously into nude mice to form tumors and were then treated with the DNA methylation inhibitor, 5-aza-2'-deoxycytidine, with and without treatment with the benzamide histone deacetylase inhibitor, entinostat (MS-275)...
August 2016: Experimental Biology and Medicine
https://www.readbyqxmd.com/read/27177222/microrna-mediated-epigenetic-targeting-of-survivin-significantly-enhances-the-antitumor-activity-of-paclitaxel-against-non-small-cell-lung-cancer
#16
Shuiliang Wang, Ling Zhu, Weimin Zuo, Zhiyong Zeng, Lianghu Huang, Fengjin Lin, Rong Lin, Jin Wang, Jun Lu, Qinghua Wang, Lingjing Lin, Huiyue Dong, Weizhen Wu, Kai Zheng, Jinquan Cai, Shunliang Yang, Yujie Ma, Shixin Ye, Wei Liu, Yinghao Yu, Jianming Tan, Bolin Liu
Elevated expression of Survivin correlates with poor prognosis, tumor recurrence, and drug resistance in various human cancers, including non-small cell lung cancer (NSCLC). The underlying mechanism of Survivin upregulation in cancer cells remains elusive. To date, no Survivin-targeted therapy has been approved for cancer treatment. Here, we explored the molecular basis resulting in Survivin overexpression in NSCLC and investigated the antitumor activity of the class I HDAC inhibitor entinostat in combination with paclitaxel...
May 10, 2016: Oncotarget
https://www.readbyqxmd.com/read/27151994/engage-501-phase-ii-study-of-entinostat-sndx-275-in-relapsed-and-refractory-hodgkin-lymphoma
#17
Connie Lee Batlevi, Yvette Kasamon, R Gregory Bociek, Peter Lee, Lia Gore, Amanda Copeland, Rachel Sorensen, Peter Ordentlich, Scott Cruickshank, Lori Kunkel, Daniela Buglio, Francisco Hernandez-Ilizaliturri, Anas Younes
Classical Hodgkin lymphoma treatment is evolving rapidly with high response rates from antibody-drug conjugates targeting CD30 and immune checkpoint antibodies. However, most patients do not achieve a complete response, therefore development of novel therapies is warranted to improve patient outcomes. In this phase II study, patients with relapsed or refractory Hodgkin lymphoma were treated with entinostat, an isoform selective histone deacetylase inhibitor. Forty-nine patients were enrolled: 33 patients on Schedule A (10 or 15 mg oral entinostat once every other week); 16 patients on Schedule B (15 mg oral entinostat once weekly in 3 of 4 weeks)...
August 2016: Haematologica
https://www.readbyqxmd.com/read/27064363/histone-deacetylase-inhibitors-decrease-nhej-both-by-acetylation-of-repair-factors-and-trapping-of-parp1-at-dna-double-strand-breaks-in-chromatin
#18
Carine Robert, Pratik K Nagaria, Nisha Pawar, Adeoluwa Adewuyi, Ivana Gojo, David J Meyers, Philip A Cole, Feyruz V Rassool
Histone deacetylase inhibitors (HDACi) induce acetylation of histone and non-histone proteins, and modulate the acetylation of proteins involved in DNA double-strand break (DSB) repair. Non-homologous end-joining (NHEJ) is one of the main pathways for repairing DSBs. Decreased NHEJ activity has been reported with HDACi treatment. However, mechanisms through which these effects are regulated in the context of chromatin are unclear. We show that pan-HDACi, trichostatin A (TSA), causes differential acetylation of DNA repair factors Ku70/Ku80 and poly ADP-ribose polymerase-1 (PARP1), and impairs NHEJ...
June 2016: Leukemia Research
https://www.readbyqxmd.com/read/27034410/functional-and-transcriptional-characterization-of-histone-deacetylase-inhibitor-mediated-cardiac-adverse-effects-in-human-induced-pluripotent-stem-cell-derived-cardiomyocytes
#19
Ivan Kopljar, David J Gallacher, An De Bondt, Laure Cougnaud, Eddy Vlaminckx, Ilse Van den Wyngaert, Hua Rong Lu
UNLABELLED: Histone deacetylase (HDAC) inhibitors possess therapeutic potential to reverse aberrant epigenetic changes associated with cancers, neurological diseases, and immune disorders. Unfortunately, clinical studies with some HDAC inhibitors displayed delayed cardiac adverse effects, such as atrial fibrillation and ventricular tachycardia. However, the underlying molecular mechanism(s) of HDAC inhibitor-mediated cardiotoxicity remains poorly understood and is difficult to detect in the early stages of preclinical drug development because of a delayed onset of effects...
May 2016: Stem Cells Translational Medicine
https://www.readbyqxmd.com/read/26980768/enhanced-histone-deacetylase-activity-in-malignant-melanoma-provokes-rad51-and-fancd2-triggered-drug-resistance
#20
Andrea Krumm, Christina Barckhausen, Pelin Kücük, Karl-Heinz Tomaszowski, Carmen Loquai, Jörg Fahrer, Oliver Holger Krämer, Bernd Kaina, Wynand Paul Roos
DNA-damaging anticancer drugs remain a part of metastatic melanoma therapy. Epigenetic reprogramming caused by increased histone deacetylase (HDAC) activity arising during tumor formation may contribute to resistance of melanomas to the alkylating drugs temozolomide, dacarbazine, and fotemustine. Here, we report on the impact of class I HDACs on the response of malignant melanoma cells treated with alkylating agents. The data show that malignant melanomas in situ contain a high level of HDAC1/2 and malignant melanoma cells overexpress HDAC1/2/3 compared with noncancer cells...
May 15, 2016: Cancer Research
keyword
keyword
79433
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"